Artivion, Inc. $AORT Stock Holdings Lowered by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL lessened its position in Artivion, Inc. (NYSE:AORT) by 36.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 68,021 shares of the company’s stock after selling 39,388 shares during the period. Tudor Investment Corp ET AL’s holdings in Artivion were worth $2,880,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Aster Capital Management DIFC Ltd increased its stake in shares of Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after purchasing an additional 519 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Artivion during the third quarter worth approximately $27,000. Smartleaf Asset Management LLC boosted its position in shares of Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after buying an additional 538 shares during the period. State of Wyoming bought a new position in Artivion in the 3rd quarter worth approximately $80,000. Finally, Quadrant Capital Group LLC acquired a new stake in Artivion in the 3rd quarter valued at approximately $92,000. 86.37% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have weighed in on AORT. Needham & Company LLC reaffirmed a “buy” rating and set a $58.00 target price on shares of Artivion in a research note on Monday, February 2nd. Stifel Nicolaus set a $55.00 price target on Artivion in a report on Thursday, March 5th. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Canaccord Genuity Group lowered their target price on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, February 13th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Artivion presently has an average rating of “Moderate Buy” and an average price target of $50.47.

Insider Transactions at Artivion

In other Artivion news, EVP Lance A. Berry sold 6,316 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $238,618.48. Following the sale, the executive vice president directly owned 210,827 shares in the company, valued at approximately $7,965,044.06. The trade was a 2.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO James P. Mackin sold 20,962 shares of the company’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $37.59, for a total transaction of $787,961.58. Following the completion of the sale, the chief executive officer directly owned 780,031 shares of the company’s stock, valued at $29,321,365.29. The trade was a 2.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 133,043 shares of company stock valued at $4,977,158 in the last three months. 7.60% of the stock is currently owned by insiders.

Artivion Stock Performance

Shares of NYSE AORT opened at $35.18 on Friday. The stock has a fifty day moving average price of $38.58 and a two-hundred day moving average price of $42.08. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. The firm has a market cap of $1.68 billion, a P/E ratio of 175.93 and a beta of 1.60. Artivion, Inc. has a 1 year low of $21.97 and a 1 year high of $48.25.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. The company had revenue of $118.30 million for the quarter, compared to the consensus estimate of $116.42 million. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The business’s quarterly revenue was up 19.2% compared to the same quarter last year. Research analysts forecast that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.